Back to Index
Amir Goldkorn, MD
Associate Professor of Medicine
NOR 3444 Health Sciences Campus Los Angeles
+1 323 442 7721


Dr. Goldkorn’s laboratory-based research program focuses on developing the therapeutic and biomarker potential of circulating tumor cells, cancer stem cells, and telomerase. Graduate students, postdocs and medical students in the laboratory conduct experiments ranging from basic molecular research to translational medicine assays for clinical trials. These research activities synergize with our clinical activities and provide unique opportunities to translate our laboratory and clinical advances into better care for our patients.

Dr. Goldkorn earned his medical degree from the UCLA School of Medicine. He then went on to complete his fellowship in hematology-oncology and post-doctoral research at University of California, San Francisco.


Harvard University: Harvard College Scholarship, 1990-1994

American Society of Clinical Oncology: Young Investigator Award, 2006-2007

UCLA School of Medicine: Letters of Distinction, 1996-1997

Western Society of Clinical Investigation: Elected Member, 2014

American Society of Clinical Oncology: Merit Award, 2012

American Federation for Medical Research: Outstanding Investigator Award, 2015

Stop Cancer Foundation: Research Career Development Award, 2007-2010


Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. View in: PubMed

Xu Y, Goldkorn A. Telomere and Telomerase Therapeutics in Cancer. Genes (Basel). 2016; 7(6). View in: PubMed

Goldkorn A. Editorial Comment. J Urol. 2015 Sep; 194(3):798. View in: PubMed

Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M. Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. J Natl Cancer Inst. 2015 Jul; 107(7). View in: PubMed

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. View in: PubMed

Hu B, Goldkorn A. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60. View in: PubMed

Agarwal N, Dorff T, Goldkorn A. New prostate cancer drugs: extending and improving life. Lancet Oncol. 2014 Sep; 15(10):1052-4. View in: PubMed

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. View in: PubMed

Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421. J Natl Cancer Inst. 2014 Apr 1; 106(4):dju013. View in: PubMed

He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/ß-catenin/CBP pathway. Int J Cancer. 2014 Jan 1; 134(1):43-54. View in: PubMed

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. View in: PubMed

Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. View in: PubMed

Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. Cancers (Basel). 2013; 5(4):1676-90. View in: PubMed

Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther. 2012 Nov; 11(11):2462-72. View in: PubMed

Xu T, He K, Wang L, Goldkorn A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate. 2011 Sep 15; 71(13):1390-400. View in: PubMed

He K, Xu T, Goldkorn A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther. 2011 Jun; 10(6):938-48. View in: PubMed

Xu Y, He K, Goldkorn A. Telomerase targeted therapy in cancer and cancer stem cells. Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. View in: PubMed

Xu T, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res. 2010 Aug 15; 70(16):6420-6. View in: PubMed

Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ther. 2010 Feb; 9(2):438-49. View in: PubMed

Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. View in: PubMed

Goldkorn A, Blackburn EH. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 2006 Jun 1; 66(11):5763-71. View in: PubMed

Powered bySC CTSI